

ASX Announcement

AdAlta receives grant of key Australian patent for AD-114

MELBOURNE Australia, 17 November, 2017: AdAlta Limited (ASX:1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce that the key patent relating to the Company's lead program, AD-114 has been granted by the Australian Patent Office.

The international application for the patent (PCT/AU2016/050005) entitled "CXCR4 binding molecules" was filed in January 2016 with a priority date of 9 January 2015. Patents are granted on a country by country basis. The grant of the Australian patent for AD-114 is a positive indication of the validity of the claims, which are being pursued internationally.

AdAlta has a portfolio of granted patents and applications that protect both the i-body technology platform and the Company's lead i-body drug candidate AD-114 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This Australian granted patent for AD-114 provides "composition of matter" protection and is valid out to 2036. It protects the use of AD-114 for the treatment of a number of diseases, including but not limited to fibrosis.

AdAlta's CEO, Sam Cobb commented, "This granted patent strengthens AdAlta's patent portfolio and position around AD-114, providing a firm footing for the commercialisation of our lead candidate. Strong protection of our intellectual property is essential to our partnering strategy and enhancing shareholder value."

Notes to Editors

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: s.cobb@adalta.com.au